Questcor Pharmaceuticals (QCOR) 93.77 $QCOR
Patient Enrollments, Board Appointments, Acquisitions, and Technical Updates - Analyst Notes on Questcor, Synta, Clovis, Alnylam and Intrexon
PR Newswire - 1 hr 14 mins ago
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Clovis Oncology, Inc. (NASDAQ: CLVS), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Intrexon Corporation (NYSE: XON). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4522-100free.
Uptrend Call Working As Questcor Pharmaceuticals Stock Rises 42.1% (QCOR)
Comtex SmarTrend(R) - Mon Jul 07, 9:22AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 3 months, Questcor Pharmaceuticals has returned 42.13% as of today's recent price of $95.81.
What Stocks Top Funds Are Buying Now
at Investor's Business Daily - Wed Jul 02, 6:09PM CDT
The country's leading funds the past three months continued to add medical and transportation stocks to their portfolios as the stock market continued to defy the economy's wall of worry. Purchases were made as the Nasdaq kicked off the summer with a...
Watch for Questcor Pharmaceuticals to Potentially Pullback After Gaining 1.33% Yesterday
Comtex SmarTrend(R) - Mon Jun 30, 3:56PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $90.24 to a high of $93.00. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $92.70 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Questcor Pharmaceuticals Up 35.0% Since SmarTrend Uptrend Call (QCOR)
Comtex SmarTrend(R) - Fri Jun 27, 11:09AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 3 months, Questcor Pharmaceuticals has returned 34.95% as of today's recent price of $90.97.
Why Small-Cap Stocks ARRIS and Questcor Have Huge Growth Potential
Selena Maranjian, The Motley Fool - Motley Fool - Thu Jun 26, 4:45PM CDT
Source: ARRIS. Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some small-cap stocks to your portfolio but don't have the time or expertise to hand-pick a few, the Vanguard...
Look for Shares of Questcor Pharmaceuticals to Potentially Rebound after Yesterday's 1.50% Sell Off
Comtex SmarTrend(R) - Thu Jun 26, 4:27PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $90.01 to a high of $92.20. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $91.08 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Questcor Pharmaceuticals Closes Transaction to Acquire International Rights to Synacthen® and Synacthen® Depot
PR Newswire - Mon Jun 23, 8:00AM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that the transaction acquiring rights to Synacthen® and Synacthen® Depot from Novartis Pharma AG and Novartis AG in certain countries outside the U.S. has now closed. Available in more than forty countries for multiple indications, Synacthen (tetracosactide) is a synthetic 24 amino acid melanocortin peptide. Synacthen Depot is a depot formulation of Synacthen. The products are approved outside the U.S. for multiple indications, including certain autoimmune and inflammatory conditions as well as for diagnostic use, but have never been developed or approved for patients in the U.S. Questcor is presently engaged in pre-clinical development for Synacthen in the U.S.
Shares of QCOR Up 38.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 20, 9:38AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 3 months, Questcor Pharmaceuticals has returned 37.98% as of today's recent price of $93.01.
Look for Shares of Questcor Pharmaceuticals to Potentially Pullback after Yesterday's 2.84% Rise
Comtex SmarTrend(R) - Tue Jun 17, 4:56PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $88.15 to a high of $91.68. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $90.99 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FDA Drug Approvals, Dividends, Fast Track Designation, Event Sponsorship, and Expansion of Role - Analyst Notes on Biogen Idec, UnitedHealth Group, GW Pharmaceuticals, Questcor and Cigna
PR Newswire - Wed Jun 11, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), UnitedHealth Group Inc. (NYSE: UNH), GW Pharmaceuticals PLC (NASDAQ: GWPH), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Cigna Corporation (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3590-100free.
Shares of QCOR Up 29.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 05, 4:46PM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 2 months, Questcor Pharmaceuticals has returned 29.45% as of today's recent price of $87.26.
Lannett Tops Trio Of Medical Small Cap Leaders
at Investor's Business Daily - Thu Jun 05, 7:02AM CDT
Small, fast-growing companies in hot industries, such as generics drugmaker Lannett, are good prospects for a stock watch list. Today's Screen Of The Day is Small Cap Leaders, highly rated companies with a market capitalization of $300 million to $2...
Pharma Stocks Review -- Research on Akorn, Questcor Pharma, Nektar Therapeutics, and Endocyte
PR Newswire - Thu Jun 05, 7:00AM CDT
On Wednesday, June 04, 2014, the NASDAQ Composite ended at 4,251.64, up 0.41%, the Dow Jones Industrial Average advanced 0.09%, to finish the day at 16,737.53, and the S&P 500 closed at 1,927.88, up 0.19%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 694.30, up 0.23%, with the index also advancing 3.81% in the last one month. Investor-Edge has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Nektar Therapeutics (NASDAQ: NKTR) and Endocyte Inc. (NASDAQ: ECYT). Free technical research on AKRX, QCOR, NKTR and ECYT can be downloaded upon signing up at:
Questcor Provides Support to Lupus Foundation of America Awareness, Education and Advocacy Efforts
PR Newswire - Tue Jun 03, 9:28AM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced its sponsorship of the Lupus Foundation of America's (LFA) eight national office Walk to End Lupus Now(TM) events and its support of a variety of Lupus Awareness Month activities.
FDA Approvals, Digital Health Guidance, Conference Presentations, and Recognitions - Analyst Notes on Intercept Pharmaceuticals, Cigna, Baxter, Questcor and Mallinckrodt
PR Newswire - Tue Jun 03, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), Cigna Corporation (NYSE: CI), Baxter International Inc. (NYSE: BAX), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Mallinckrodt PLC (NYSE: MNK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3242-100free.
SmarTrend Watching for Potential Pullback in Shares of Questcor Pharmaceuticals After 1.43% Gain
Comtex SmarTrend(R) - Mon Jun 02, 4:25PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $89.51 to a high of $92.38. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $90.50 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Kors, Qihoo Among 5 Top Stocks With 99 EPS Ratings
at Investor's Business Daily - Thu May 29, 7:02AM CDT
Michael Kors continued to show its dominance in the luxury-brand market, posting fourth-quarter earnings that topped analyst estimates Wednesday. The company is among highly rated firms that have strong long-term fundamentals. The Top Fundamentals...
Patient Enrollments, Board Appointments, Acquisitions, and Technical Updates - Analyst Notes on Questcor, Synta, Clovis, Alnylam and Intrexon
PR Newswire - 1 hr 14 mins ago
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Clovis Oncology, Inc. (NASDAQ: CLVS), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Intrexon Corporation (NYSE: XON). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4522-100free.
Uptrend Call Working As Questcor Pharmaceuticals Stock Rises 42.1% (QCOR)
Comtex SmarTrend(R) - Mon Jul 07, 9:22AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 3 months, Questcor Pharmaceuticals has returned 42.13% as of today's recent price of $95.81.
What Stocks Top Funds Are Buying Now
at Investor's Business Daily - Wed Jul 02, 6:09PM CDT
The country's leading funds the past three months continued to add medical and transportation stocks to their portfolios as the stock market continued to defy the economy's wall of worry. Purchases were made as the Nasdaq kicked off the summer with a...
Watch for Questcor Pharmaceuticals to Potentially Pullback After Gaining 1.33% Yesterday
Comtex SmarTrend(R) - Mon Jun 30, 3:56PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $90.24 to a high of $93.00. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $92.70 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Questcor Pharmaceuticals Up 35.0% Since SmarTrend Uptrend Call (QCOR)
Comtex SmarTrend(R) - Fri Jun 27, 11:09AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 3 months, Questcor Pharmaceuticals has returned 34.95% as of today's recent price of $90.97.
Why Small-Cap Stocks ARRIS and Questcor Have Huge Growth Potential
Selena Maranjian, The Motley Fool - Motley Fool - Thu Jun 26, 4:45PM CDT
Source: ARRIS. Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some small-cap stocks to your portfolio but don't have the time or expertise to hand-pick a few, the Vanguard...
Look for Shares of Questcor Pharmaceuticals to Potentially Rebound after Yesterday's 1.50% Sell Off
Comtex SmarTrend(R) - Thu Jun 26, 4:27PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $90.01 to a high of $92.20. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $91.08 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Questcor Pharmaceuticals Closes Transaction to Acquire International Rights to Synacthen® and Synacthen® Depot
PR Newswire - Mon Jun 23, 8:00AM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that the transaction acquiring rights to Synacthen® and Synacthen® Depot from Novartis Pharma AG and Novartis AG in certain countries outside the U.S. has now closed. Available in more than forty countries for multiple indications, Synacthen (tetracosactide) is a synthetic 24 amino acid melanocortin peptide. Synacthen Depot is a depot formulation of Synacthen. The products are approved outside the U.S. for multiple indications, including certain autoimmune and inflammatory conditions as well as for diagnostic use, but have never been developed or approved for patients in the U.S. Questcor is presently engaged in pre-clinical development for Synacthen in the U.S.
Shares of QCOR Up 38.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 20, 9:38AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 3 months, Questcor Pharmaceuticals has returned 37.98% as of today's recent price of $93.01.
Look for Shares of Questcor Pharmaceuticals to Potentially Pullback after Yesterday's 2.84% Rise
Comtex SmarTrend(R) - Tue Jun 17, 4:56PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $88.15 to a high of $91.68. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $90.99 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FDA Drug Approvals, Dividends, Fast Track Designation, Event Sponsorship, and Expansion of Role - Analyst Notes on Biogen Idec, UnitedHealth Group, GW Pharmaceuticals, Questcor and Cigna
PR Newswire - Wed Jun 11, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), UnitedHealth Group Inc. (NYSE: UNH), GW Pharmaceuticals PLC (NASDAQ: GWPH), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Cigna Corporation (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3590-100free.
Shares of QCOR Up 29.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 05, 4:46PM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 2 months, Questcor Pharmaceuticals has returned 29.45% as of today's recent price of $87.26.
Lannett Tops Trio Of Medical Small Cap Leaders
at Investor's Business Daily - Thu Jun 05, 7:02AM CDT
Small, fast-growing companies in hot industries, such as generics drugmaker Lannett, are good prospects for a stock watch list. Today's Screen Of The Day is Small Cap Leaders, highly rated companies with a market capitalization of $300 million to $2...
Pharma Stocks Review -- Research on Akorn, Questcor Pharma, Nektar Therapeutics, and Endocyte
PR Newswire - Thu Jun 05, 7:00AM CDT
On Wednesday, June 04, 2014, the NASDAQ Composite ended at 4,251.64, up 0.41%, the Dow Jones Industrial Average advanced 0.09%, to finish the day at 16,737.53, and the S&P 500 closed at 1,927.88, up 0.19%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 694.30, up 0.23%, with the index also advancing 3.81% in the last one month. Investor-Edge has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Nektar Therapeutics (NASDAQ: NKTR) and Endocyte Inc. (NASDAQ: ECYT). Free technical research on AKRX, QCOR, NKTR and ECYT can be downloaded upon signing up at:
Questcor Provides Support to Lupus Foundation of America Awareness, Education and Advocacy Efforts
PR Newswire - Tue Jun 03, 9:28AM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced its sponsorship of the Lupus Foundation of America's (LFA) eight national office Walk to End Lupus Now(TM) events and its support of a variety of Lupus Awareness Month activities.
FDA Approvals, Digital Health Guidance, Conference Presentations, and Recognitions - Analyst Notes on Intercept Pharmaceuticals, Cigna, Baxter, Questcor and Mallinckrodt
PR Newswire - Tue Jun 03, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), Cigna Corporation (NYSE: CI), Baxter International Inc. (NYSE: BAX), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Mallinckrodt PLC (NYSE: MNK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3242-100free.
SmarTrend Watching for Potential Pullback in Shares of Questcor Pharmaceuticals After 1.43% Gain
Comtex SmarTrend(R) - Mon Jun 02, 4:25PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $89.51 to a high of $92.38. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $90.50 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Kors, Qihoo Among 5 Top Stocks With 99 EPS Ratings
at Investor's Business Daily - Thu May 29, 7:02AM CDT
Michael Kors continued to show its dominance in the luxury-brand market, posting fourth-quarter earnings that topped analyst estimates Wednesday. The company is among highly rated firms that have strong long-term fundamentals. The Top Fundamentals...
